Sodium tetradecyl sulfate 0.2% solution for injection 5ml vials
An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Sodium tetradecyl sulfate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 4 · 1963–2026
Showing the 50 most relevant studies, sorted by most relevant.
Nocini R, Muneretto C, Arsie AE, et al.
2026
BackgroundLow-flow vascular malformations (LFVMs) of the head and neck, including venous and lymphatic malformations, represent a heterogeneous group of congenital anomalies frequently requiring intervention due to functional and esthetic impairment. Percutaneous sclerotherapy has emerged as a first-line treatment; however, no consensus exists regarding the optimal sclerosant, and all agents are associated with potential complications. This systematic review aims to evaluate and compare the safety profiles of commonly used sclerosing agents in the management of LFVMs of the head and neck.MethodsA systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Google Scholar were searched for studies published between 2005 and 2025 reporting complications of sclerotherapy for LFVMs of the head and neck. Inclusion criteria comprised clinical studies with patients treated with intralesional sclerotherapy as a single modality and reporting treatment-related complications. Data extraction focused on type of malformation, sclerosant used, number of sessions, and complication rates per session. Complications were categorized as local or systemic and further stratified into minor and major events.ResultsA total of 64 studies encompassing 2508 patients and 5193 sclerotherapy sessions were included. The overall complication rate was 11.2% per session, with the majority being minor local events (8.8%). Bleomycin was the most frequently used agent (1516 sessions; 13.5% complication rate), predominantly associated with mild local and systemic inflammatory reactions. Ethanol (1072 sessions; 9%) demonstrated higher rates of major local complications (1.7%), including tissue necrosis and permanent nerve injury, as well as systemic effects such as hemoglobinuria and rare cardiopulmonary events. Sodium tetradecyl sulfate (STS) (1061 sessions; 9.5%) showed a moderate complication profile but carried risks of necrosis and airway edema. Polidocanol (860 sessions; 4.2%) and doxycycline (158 sessions; 3.8%) exhibited the most favorable safety profiles, with no major complications reported. Ethanolamine oleate had the highest complication rate (20.2%), including significant local adverse events.ConclusionsSclerotherapy for LFVMs of the head and neck is generally safe, with most complications being minor and self-limiting. However, the safety profile varies significantly among sclerosants. Given the absence of standardized guidelines and comparative efficacy data, safety considerations should play a central role in sclerosant selection.
Abstract licence: CC BY
Bukina OV, Sinitsyn AA, Efremova OI, et al.
2023
- Telangiectasis
- Sodium Tetradecyl Sulfate
- Sclerosing Solutions
Kazunori Okutani, Yui Kuwabara, Yasuhiko H. Mori
Chemical Engineering Science, 2007
A. Blank, Ruth H. Sugiyama, Charles A. Dekker
Analytical Biochemistry, 1982
- 1-Propanol
- Cattle
- Deoxyribonucleases
Velia Ramírez‐Amador, Lilly Esquivel‐Pedraza, Francina Lozada‐Nur, et al.
Oral Oncology, 2002
- Antineoplastic Agents, Phytogenic
- Mouth Neoplasms
- Sarcoma, Kaposi
Jeffry Yoslim, Praveen Linga, Peter Englezos
Journal of Crystal Growth, 2010
O. V. Bukina, A. A. Sinitsyn, A.V. Pelevin
Vascular Medicine, 2021
- Sodium Tetradecyl Sulfate
- Telangiectasis
- Glucose
K.-Y. Chang, Chih-Sheng Wu, P. C. Chen
Endoscopy, 1996
- Sclerosing Solutions
- Esophageal and Gastric Varices
- Gastrointestinal Hemorrhage
Helena Jenkinson, Kelly M. Wilmas, Sirunya Silapunt
Dermatologic Surgery, 2017
- Off-Label Use
- Sclerosing Solutions
- Sodium Tetradecyl Sulfate
J. Crossan O'Donovan, John Donaldson, Frank P. Morello, et al.
American Journal of Roentgenology, 1997
- Arteriovenous Malformations
- Hemangioma
- Injections
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Proteins and enzymes this drug interacts with in the body
PMID:25618265
Exerts a protective effect on the endothelial cell barrier function PMID:25651845
ATC C05BB04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Sodium tetradecyl sulfate
Additional database identifiers
Drugs Product Database (DPD)
6212
ChemSpider
8440
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9456
GenAtlas
PROS1
GeneCards
PROS1
GenBank Gene Database
M15036
GenBank Protein Database
190289
UniProt Accession
PROS_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9451
GenAtlas
PROC
GeneCards
PROC
GenBank Gene Database
M11228
GenBank Protein Database
190334
Guide to Pharmacology
2396
UniProt Accession
PROC_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q20817018), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.